Process development of ABT-450 – A first generation NS3/4A protease inhibitor for HCV

Add time:09/01/2019    Source:sciencedirect.com

ABT-450 (8), a potent hepatitis C (HCV) NS3/4A protease inhibitor, was approved as part of AbbVie's first generation HCV treatment for the United States in December 2014. A series of process optimizations were developed over six years to support the program starting with recycling of a previous protease inhibitor candidate through route development and final process. This discussion will focus on optimization of the final six steps starting from dipeptide 12 and amino acid 13 and highlights the use of a large scale ring closing metathesis (RCM), reactive crystallizations for isolation of intermediates, and detailed process understanding of the final sulfonamide coupling. The process provides ABT-450 (8) in 72% overall yield for the final 6 steps.

We also recommend Trading Suppliers and Manufacturers of ABTS (cas 19617-05-1). Pls Click Website Link as below: cas 19617-05-1 suppliers

Prev:Graphene enhanced transformation of lignin in laccase-ABTS (cas 19617-05-1) system by accelerating electron transfer
Next:ORIGINAL ARTICLEThe ABTS (cas 19617-05-1) 10-year Maintenance of Certification Exam Improves and Validates Knowledge Acquisition)